Singular Health Raises $8M, Secures $2M US Contract, Boosts Compliance

Singular Health has landed a pivotal $2 million US pilot contract with Provider Network Solutions and completed an $8 million capital raise, advancing its medical imaging platform’s regulatory and product development milestones.

  • USD $1.3M contract signed with Provider Network Solutions for US pilot
  • Completed AUD $8M capital raise led by Wallabi Group
  • Achieved ISO 13485, SOC 2 Type 2, and HIPAA certifications
  • Expanded US market opportunities validated through research and site visits
  • Strong cash position of AUD $13.7M with zero debt
An image related to Singular Health Group Ltd
Image source middle. ©

US Market Breakthrough with Provider Network Solutions

Singular Health Group Limited (ASX, SHG) marked a significant milestone in the June 2025 quarter by securing a USD $1.3 million (approximately AUD $2 million) commercial pilot contract with Provider Network Solutions (PNS), a major Managed Service Organisation overseeing care for over 3.7 million individuals. This agreement advances the company into Phase III of its multi-phase engagement with PNS, following a year of rigorous technical and clinical validation of its 3DICOM™ platform.

The pilot will distribute 1,000 3DICOM™ MD licenses to primary care providers in Puerto Rico and Florida, aiming to streamline medical imaging access, reduce redundant scans, and accelerate diagnostic workflows within MSO networks. Executives also showcased the platform’s core components to other MSOs, sparking further commercial interest that could broaden Singular Health’s footprint across more than 30 US states.

Capital Raise and Regulatory Certifications Strengthen Position

Backing its US expansion, Singular Health completed an AUD $8 million capital raise led by the Wallabi Group, with participation from PNS and Marin and Sons. This infusion bolsters the company’s balance sheet, reflected in a strong cash holding of AUD $13.7 million and zero debt at quarter’s end.

On the compliance front, the company achieved ISO 13485 re-certification, SOC 2 Type 2, and HIPAA compliance, critical certifications for operating within the highly regulated US healthcare environment. Efforts are underway to secure FDA clearance for its 3DICOM™ online viewer, complementing its already approved desktop viewer, further enhancing its regulatory readiness.

Expanding US and Australian Market Opportunities

Beyond the PNS pilot, Singular Health is actively pursuing multiple commercial proposals with US educational institutions and healthcare providers interested in leveraging its platform for imaging data aggregation and simulation-based teaching programs. Discussions with major health funds like Triple-S in Puerto Rico and Barry University for student-athlete medical management pilots underscore growing interest.

Domestically, the company is advancing initiatives to improve medical imaging data access and clinical training through government and radiology stakeholder engagement. These efforts aim to address inefficiencies in Australia’s fragmented imaging data landscape, positioning Singular Health for sustained global growth.

Product Innovation and Strategic Partnerships

Technical development progressed with the release of a redesigned clinical viewer, integration of an AI marketplace, and enhanced PDF upload capabilities to support pilot requirements. The recent appointment of Dr. Alex Alonso, a US-based radiology consultant, to oversee PACS integration and validate the 3DICOM™ platform at Life Radiology in Florida adds clinical credibility and operational insight to the company’s US rollout.

These combined advances in product, partnerships, and regulatory compliance create a robust foundation for Singular Health’s ambition to become a key digital infrastructure provider to MSOs and primary care networks across the US.

Bottom Line?

With a strong cash position and validated US market entry, Singular Health is poised for transformative growth, pending pilot outcomes and FDA clearance.

Questions in the middle?

  • How will the PNS pilot results influence broader national deployment across US MSOs?
  • What is the timeline and likelihood for FDA clearance of the 3DICOM™ online viewer?
  • How will ongoing US educational sector proposals translate into commercial contracts?